Vor Bio is licensing global rights a fusion protein that inhibits two targets to potentially treat the neuromuscular disorder generalized myasthenia gravis. It’s a pivot for Vor, which last month ceased its cancer R&D and announced it would explore strategic alternatives.
The post Vor Bio Reinvents Itself as an Autoimmune Biotech With In-Licensed Phase 3 Asset and $175M in Funding appeared first on MedCity News.
